Search results for "INRA"

showing 10 items of 84 documents

SAT0511 CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: CLINICAL INACTIVE DISEASE RATE AND SAFETY IN ITALIAN PATIENTS

2019

Background: Systemic juvenile idiopathic arthritis (sJIA) is a polygenic autoinflammatory disease. The innate immune mechanisms play a central role with overproduction of inflammatory cytokines. The increased knowledge on the role of these cytokines has provided a change in the natural history of the disease with the introduction of the targeted treatments. Remarkable results has been observed with canakinumab, an anti-interleukin-1β monoclonal antibody, in two clinical trials but little information are available in real life. Objectives: To evaluate clinical inactive disease rate and safety of canakinumab in Italian patients with sJIA. Methods: We have collected retrospectively clinical an…

medicine.medical_specialtyAnakinraeducation.field_of_studybusiness.industryPopulationmedicine.diseaseRashEtanerceptchemistry.chemical_compoundCanakinumabTocilizumabchemistryMacrophage activation syndromeInternal medicineInjection site reactionMedicinemedicine.symptombusinesseducationmedicine.drugSaturday, 15 June 2019
researchProduct

FRI0504 Prognostic Factors of Adult Onset Still's Disease: Analysis of 100 Cases in 3 Tertiary Referral Centers

2016

Background Adult onset Still9s disease (AOSD) is rare inflammatory disease [1]. Three different patterns of AOSD have been identified: i. monocyclic pattern, characterized by a systemic single episode; ii. polycyclic pattern, associated with multiple flares, separated by remissions; iii. chronic pattern, related to a persistently active disease with associated polyarthritis [2]. Until now, the treatment of AOSD remains largely empirical, lacking controlled clinical trials [1]. Objectives We aimed to investigate clinical data of AOSD patients and any possible correlation among these features and the outcome of patients. Methods Clinical data of 100 AOSD patients were recorded. All patients f…

medicine.medical_specialtyImmunologyArthritisGeneral Biochemistry Genetics and Molecular Biology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTocilizumabRheumatologyInternal medicinemedicineImmunology and Allergy030212 general & internal medicine030203 arthritis & rheumatologyAnakinramedicine.diagnostic_testbusiness.industrymedicine.diseaseRashSurgerychemistryErythrocyte sedimentation rateMacrophage activation syndromePolyarthritismedicine.symptombusinessComplicationmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort

2021

Abstract Objective The objective of this study was to use real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with systemic JIA (sJIA). Methods A retrospective multicentre study of children with sJIA was performed. Clinical features, laboratory parameters and adverse events were collected at baseline, and 6 and 12 months after starting canakinumab. The primary outcome measure of effectiveness was clinically inactive disease (CID) off glucocorticoids (GCs) treatment at 6 months. Results A total of 80 children from 15 Italian centres were analysed. Of the 12 patients who started canakinumab in CID while receiving anakinra, all maintained CID. Of the 68 …

medicine.medical_specialtyMultivariate analysissystemic juvenile idiopathic arthritisArthritisJuvenileAntibodies Monoclonal HumanizedcanakinumabAntibodiessystemic juvenile idiopathic arthritis.Settore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicineMonoclonalmedicinecanakinumab; clinically inactive disease; systemic juvenile idiopathic arthritis; Antibodies Monoclonal Humanized; Child; Glucocorticoids; Humans; Retrospective Studies; Arthritis Juvenile; Macrophage Activation SyndromeHumanscanakinumab clinically inactive disease systemic juvenile idiopathic arthritis Antibodies Monoclonal Humanized Child Glucocorticoids Humans Retrospective Studies Arthritis Juvenile Macrophage Activation SyndromePharmacology (medical)clinical inactive disease.Adverse effectChildHumanizedGlucocorticoidsRetrospective StudiesUnivariate analysisAnakinrabusiness.industryclinically inactive diseaseArthritisMacrophage Activation Syndromemedicine.diseaseArthritis JuvenileCanakinumabMacrophage activation syndromeCohortSystemic juvenile idiopathic arthritibusinessmedicine.drug
researchProduct

A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwi…

2016

Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic options in a large number of old and new clinical entities characterized by an IL-1 driven pathogenesis. Objectives: To perform a nationwide snapshot of the on-label and off-label use of anakinra (ANA) and canakinumab (CAN) for different conditions both in children and adults. Methods: We retrospectively collected demographic, clinical, and therapeutic data from both adult and pediatric patients treated with IL-1 inhibitors from January 2008 to July 2016. Results: Five hundred and twenty-six treatment courses given to 475 patients (195 males, 280 females; 111 children and 364 adults) were evaluated. ANA wa…

medicine.medical_specialtyautoinflammatory disorders treatment interleukin (IL)-1 anakinra canakinumabDoseanakinra; autoinflammatory disorders; canakinumab; interleukin (IL)-1; treatmentautoinflammatory disorders; treatment; interleukin (IL)-1; anakinra; canakinumab030204 cardiovascular system & hematologyOff-label usecanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInternal medicinemedicinePharmacology (medical)Interleukin-1 inhibitorsAdverse effectOriginal Research030203 arthritis & rheumatologyPharmacologyAnakinratreatmentbusiness.industrylcsh:RM1-950Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin (IL)-1; Treatment; Pharmacology; Pharmacology (medical)InterleukinRetrospective cohort studySurgeryinterleukin (IL)-1Canakinumablcsh:Therapeutics. PharmacologyAutoinflammatory disorderSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAautoinflammatory disordersAntirheumatic drugsbusinessmedicine.druganakinra
researchProduct

2020

The biological anakinra appears promising to halt cytokine storm syndrome seen in severe courses of COVID-19. However, immunosuppression with anakinra may facilitate sepsis, necessitating continuous screening for bacterial superinfections.

musculoskeletal diseasesAnakinra2019-20 coronavirus outbreakARDSCoronavirus disease 2019 (COVID-19)medicine.drug_classbusiness.industrymedicine.medical_treatmentImmunosuppressionGeneral Medicine030204 cardiovascular system & hematologymedicine.diseaseReceptor antagonistSepsis03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisImmunologymedicineCytokine stormbusinessmedicine.drugClinical Case Reports
researchProduct

Mitä opettaa ja miten? : musiikin opetussuunnitelmaa rakentamassa esikouluopettajien koulutukseen Swazimaassa

2014

Tutkielma käsittelee musiikin opetussuunnitelman tekoprosessia ja toteuttamista esikouluopettajille itselle vieraassa kulttuurissa yhteistyössä paikallisten ihmisten kanssa. Tutkimuksen tavoitteena oli suunnitella mahdollisimman hyvin maan koulutuksen tarpeita vastaava musiikinkurssi esikouluopettajia ympäri Swazimaata kouluttavalle EduGate-projektille selvittämällä millaisia asioita musiikista Swazimaalaisille esikouluopettajille olisi hyödyllistä opettaa. Käytin lähtökohtana suomalaisen varhaismusiikkikasvatuksen opsin tavoitteita ja sisältöjä, joista muokkasin opiskelijoille teetetyn kyselyn, koulutuksen järjestäjien toiveiden, Swazimaasta keräämäni informaation ja omien näkemysteni peru…

musiikkikasvatusvarhaisiän musiikkikasvatusSwazimaaopetusopetussuunnittelumonikulttuurisuusesikoulukehitysyhteistyösoitinrakennuskehitysapuopettajankoulutusopetusmateriaaliopetussuunnitelmatkulttuurienvälisyysoppimateriaali
researchProduct

Penning-trap mass measurements on 92, 94-98, 100Mo with JYFLTRAP

2012

Penning-trap measurements on stable 92, 94-98, 100Mo isotopes have been performed with relative accuracy of \ensuremath1⋅10−8\ensuremath1⋅10−8 with the JYFLTRAP Penning-trap mass spectrometer by using 85Rb as a reference. The Mo isotopes have been found to be about 3keV more bound than given in the Atomic Mass Evaluation 2003 (AME03). The results confirm that the discrepancy between the ISOLTRAP and JYFLTRAP data for 101-105Cd isotopes was due to an erroneous value in the AME03 for 96Mo used as a reference at JYFLTRAP. The measured frequency ratios of Mo isotopes have been used to update mass-excess values of 30 neutron-deficient nuclides measured at JYFLTRAP. peerReviewed

nuclear spectroscopyPhysicsNuclear and High Energy PhysicsMass excessIsotopeaccelerator-based physicsPenning trapMass spectrometrykiihdytinpohjainen fysiikkaISOLTRAPAtomic massNuclear physicsydinrakennenuclear structureydinspektroskopiaNuclear fusionNuclideAtomic physicsydinfysiikkaThe European Physical Journal A
researchProduct

Mass measurements of neutron-deficient nuclei and their implications for astrophysics

2012

During the years 2005-2010 the double-Penning-trap mass spectrometer JYFLTRAP has been used to measure the masses of 90 ground and 8 isomeric states of neutron-deficient nuclides with a typical precision of better than 10keV. The masses of 14 nuclides -- 84Zr , 88, 89Tc , 90-92Ru , 92-94Rh , 94, 95Pd , 106, 108, 110Sb -- have been experimentally determined for the first time. This article gives an overview on these measurements and their impact on the modeling of the astrophysical rp -process. peerReviewed

nuclear spectroscopyPhysicsNuclear and High Energy PhysicsMass excessaccelerator-based physicsHadronMeasure (physics)Mass spectrometrykiihdytinpohjainen fysiikkaMass measurementNuclear physicsydinrakennenuclear structureydinspektroskopiaNuclear fusionNeutronNuclideydinfysiikkaThe European Physical Journal A
researchProduct

Underground multi-muon experiment EMMA

2011

EMMA is a new experiment designed for cosmic-ray composition studies around the knee energy operating at the shallow depth underground in the Pyhäsalmi mine, Finland. The array has sufficient coverage and resolution to determine the multiplicity, the lateral density distribution and the arrival direction of high-energy muons on an event by event basis. Preliminary results on the muon multiplicity extracted using one detector station of the array are presented. peerReviewed

nuclear spectroscopyPhysics::Instrumentation and Detectorsaccelerator-based physicsmaanalainen fysiikkamyonitKosmiset säteetkiihdytinpohjainen fysiikkaastrohiukkasfysiikkaydinrakennenuclear structureydinspektroskopiaHigh Energy Physics::Experimentpolviydinfysiikka
researchProduct

Precise Determination of the Unperturbed 8B Neutrino Spectrum

2012

The measurement was performed at the Kernfysisch Versneller Instituut (KVI) at the University of Groningen, The Netherlands.; A measurement of the final state distribution of the 8B $\beta$ decay, obtained by implanting a 8B beam in a double-sided silicon strip detector, is reported here. The present spectrum is consistent with a recent independent precise measurement performed by our collaboration at the IGISOL facility, Jyvâskylä [O. S. Kirsebom et al., Phys. Rev. C 83, 065802 (2011)]. It shows discrepancies with previously measured spectra, leading to differences in the derived neutrino spectrum. Thanks to a low detection threshold, the neutrino spectrum is for the first time directly ex…

nuclear spectroscopyneutrino oscillationsPhysics::Instrumentation and Detectorsaccelerator-based physics[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]kiihdytinpohjainen fysiikkaKVIydinrakenne8Bnuclear structureydinspektroskopiaimplantationydinfysiikka23.40.Bw 26.65.+t 27.20.+nbeta-decay
researchProduct